Robenacoxib
5-ethyl-2-[(2,3,5,6-tetrafluorophenyl)amino]phenyl acetic acid
También conocido como: Onsior · robenacoxibum · robénacoxib
Revisado por el equipo veterinario de VetSheetActualizado 5 abr 2026Referencia veterinaria basada en la evidencia
Las dosis son una referencia clínica para profesionales veterinarios autorizados. Confirme siempre con el prospecto actual y cada paciente individual.
Dosis por especie
🌎 NA — North America🌍 EU — Europe
Perros
| Indicación | Dosis | Vía | Frecuencia | Duración | Región |
|---|---|---|---|---|---|
| Pain and inflammation associated with chronic osteoarthritis | 1 mg/kg with a range of 1-2 mg/kg | PO | once daily | Discontinue after 10 days if no clinical improvement seen | 🌎 NA |
| Pain and inflammation associated with orthopedic or soft tissue surgery | 2 mg/kg | SC | once | — | 🌎 NA |
| Perioperative analgesia (orthopaedic and soft tissue surgery) | 2 mg/kg | SC | q24h | Maximum of 2 doses | 🌍 EU |
| Acute and chronic musculoskeletal disorders | 1-2 mg/kg | PO | q24h | Discontinue after 10 days if no clinical improvement | 🌍 EU |
- Pain and inflammation associated with chronic osteoarthritis: Give at the same time every day. For long term treatment, can adjust to lowest effective dose.
- Pain and inflammation associated with orthopedic or soft tissue surgery: Administer approximately 30 minutes before the start of surgery.
- Perioperative analgesia (orthopaedic and soft tissue surgery): Administer approximately 30 minutes before the start of surgery.
- Acute and chronic musculoskeletal disorders: Do not administer with food. Monitoring is recommended for long-term treatment (>12 weeks).
Gatos
| Indicación | Dosis | Vía | Frecuencia | Duración | Región |
|---|---|---|---|---|---|
| Acute pain and inflammation associated with musculoskeletal disorders | 1 mg/kg; with a range of 1-2.4 mg/kg | PO | once daily | up to 6 days | 🌎 NA |
| Pain and inflammation associated with chronic osteoarthritis (Note: Label likely intended for surgical pain based on injection formulation) | 2 mg/kg | SC | once | — | 🌎 NA |
| Perioperative analgesia | 2 mg/kg | SC | q24h | Maximum of 2 doses | 🌍 EU |
| Acute and chronic musculoskeletal pain and inflammation | 1-2 mg/kg | PO | q24h | As directed by veterinarian | 🌍 EU |
- Acute pain and inflammation associated with musculoskeletal disorders: Equates to 1 tablet for cats weighing 2.5-<6 kg and 2 tablets for cats weighing 6 kg-<12 kg. Give either without food or with a small amount of food; tablets should not be divided or broken.
- Pain and inflammation associated with chronic osteoarthritis (Note: Label likely intended for surgical pain based on injection formulation): Administer approximately 30 minutes before the start of surgery.
- Perioperative analgesia: Administer approximately 30 minutes before the start of surgery.
- Acute and chronic musculoskeletal pain and inflammation: May be mixed with a small amount of food. Monitoring is recommended for long-term treatment (>12 weeks).
Las dosis son una referencia clínica para profesionales veterinarios autorizados. Confirme siempre con el prospecto actual y cada paciente individual.
Resumen
Robenacoxib es un antiinflamatorio no esteroideo (AINE) de la clase coxib altamente selectivo, autorizado específicamente para su uso en perros y gatos.
Las características clínicas clave incluyen:
- Selectividad tisular: Presenta un perfil farmacocinético único donde se elimina rápidamente del compartimento sanguíneo central, pero persiste en concentraciones más altas y durante periodos más prolongados en los sitios de inflamación activa (como articulaciones inflamadas). Este efecto de "protección tisular" ayuda a maximizar la eficacia mientras se minimizan los efectos adversos sistémicos.
- Alta especificidad por COX-2: Es aproximadamente 140 veces más selectivo por la COX-2 en perros y 500 veces más selectivo en gatos en comparación con la COX-1, lo que lo convierte en uno de los AINE más específicos para COX-2 disponibles en medicina veterinaria.
- Indicaciones: Utilizado principalmente para el manejo del dolor crónico por osteoartritis en perros, dolor musculoesquelético agudo en gatos y dolor perioperatorio asociado con cirugías de tejidos blandos u ortopédicas en ambas especies.
Mecanismo de acción
Robenacoxib exerts its anti-inflammatory and analgesic effects by selectively inhibiting the Cyclooxygenase-2 (COX-2) enzyme.
Arachidonic Acid → COX-2 Enzyme → Prostaglandin E2 (PGE2) and other inflammatory mediators.
By specifically targeting the inducible COX-2 isoform, robenacoxib effectively blunts the production of prostaglandins responsible for pain, inflammation, and fever. Because it largely spares the constitutive COX-1 enzyme, it preserves the homeostatic prostaglandins that are crucial for maintaining gastrointestinal mucosal integrity, renal blood flow, and normal platelet function.
Seguridad y advertencias
Contraindicaciones
- Patients with active gastrointestinal ulcers
- Hypersensitivity to robenacoxib or its excipients
- Dogs with hepatic disease
- Dehydrated, hypovolaemic, or hypotensive patients
- Patients with pre-existing gastrointestinal disease or ulceration
- Patients with blood clotting disorders
- Pregnant or lactating animals
- Dogs < 12 weeks of age or < 2.5 kg body weight
- Cats < 16 weeks of age or < 2.5 kg body weight
- Perioperative use in animals with renal disease (not advisable)
Efectos adversos
- Decreased appetite
- Blood in feces (melena/hematochezia)
- Mild gastrointestinal signs (vomiting, soft feces, diarrhea)
- Gastrointestinal ulceration or bleeding (rare but severe)
- Renal toxicity (especially if hypotensive or dehydrated)
- Hepatic accumulation (in patients with pre-existing liver disease)
Precauciones
Strict Veterinary Monitoring Required: Use with extreme caution in patients with impaired cardiac or renal function, dehydration, hypovolemia, hypotension, or in cats with hepatic dysfunction.
- Washout Period: Do not use concurrently with corticosteroids or other NSAIDs. A treatment-free period of at least 24 hours (accounting for the half-life of the previous drug) should be observed before starting robenacoxib.
- Renal Perfusion: Use cautiously with drugs that affect renal blood flow (e.g., diuretics, ACE inhibitors) due to the risk of renal toxicity.
- Reproduction: Safety has not been established in pregnant or lactating animals; use is not recommended.
Interacciones farmacológicas
Some NSAIDs can reduce effects on blood pressure
May increase the risk of gastrointestinal toxicity (e.g., ulceration, bleeding, vomiting, diarrhea)
May increase the risk of gastrointestinal toxicity (e.g., ulceration, bleeding, vomiting, diarrhea)
NSAIDs may increase serum levels
Administration has increased plasma levels of celecoxib in humans and potentially could also affect robenacoxib levels in dogs
NSAIDs may reduce the saluretic and diuretic effects
As robenacoxib is highly bound to plasma proteins (>99%), it may displace other highly bound drugs or be displaced by them, potentially leading to increased serum levels and toxicity
Serious toxicity has occurred when NSAIDs have been used concomitantly; use together with extreme caution
May enhance the risk of nephrotoxicity development
Increased risk of severe gastrointestinal ulceration and renal toxicity. Require a 3-5 day wash-out period.
Increased risk of severe gastrointestinal ulceration and bleeding.
Increased risk of nephrotoxicity.
Monitorización
- Baseline and periodic physical examinations to assess clinical efficacy and adverse effects
- Baseline and periodic CBC, serum biochemistry (liver and renal function), electrolytes, and urinalysis
- For long-term therapy in dogs: Monitor liver enzymes at the start of therapy, and after 2, 4, and 8 weeks; then every 3-6 months
- Discontinue therapy if liver enzymes increase markedly or if accompanied by clinical signs (anorexia, apathy, vomiting)
- Clinical response (reduction in pain and inflammation)
- Gastrointestinal signs (monitor for vomiting, diarrhea, or melena)
- Renal parameters (BUN, Creatinine, USG) and hepatic enzymes, especially prior to anesthesia or during long-term therapy (>12 weeks)
Farmacocinética
Vida media
Absorción
Peak blood concentrations occur approximately 30 minutes after dosing in both dogs and cats. In dogs, food decreases peak levels somewhat. In cats, a small amount of food does not impact absorption.
Distribución
Highly bound to plasma proteins (>99%). Robenacoxib persists longer and at higher concentrations at sites of inflammation (e.g., inflamed joints) than in the central blood compartment.
Metabolismo
Extensively metabolized by the liver in both dogs and cats. It does not appear to induce hepatic enzymes in dogs.
Eliminación
In dogs, excretion is primarily biliary (~65%) with the remainder excreted renally. In cats, elimination is 70% biliary and 30% renal.
Sobredosis
Acute overdoses may potentially cause gastrointestinal, kidney, or liver toxicity.
Interestingly, chronic toxicity studies in healthy young dogs (up to 10 mg/kg/day for 6 months) and cats (up to 10 mg/kg SC for 3 days) did not produce signs of toxicity.
Treatment: If an acute overdose occurs, symptomatic and supportive therapy is recommended. This may include the administration of gastrointestinal protective agents (e.g., sucralfate, omeprazole), IV fluid therapy for forced diuresis and renal support, and contacting an animal poison control center for guided management.
Productos disponibles
Formulaciones
- Flavored oral tablets (canine and feline)
- Solution for injection
- 5 mg flavoured tablets (dogs)
- 10 mg flavoured tablets (dogs)
- 20 mg flavoured tablets (dogs)
- 40 mg flavoured tablets (dogs)
- 6 mg flavoured tablets (cats)
- 20 mg/ml injectable solution
Veterinario
- Robenacoxib Flavored Oral Tablets (dogs): 5 mg, 10 mg, 20 mg, 40 mg
- Robenacoxib Flavored Tablets (cats): 6 mg
- Robenacoxib Solution for Injection: 20 mg/mL in 20 mL multi-dose vials
- Onsior 5 mg flavoured tablets for dogs
- Onsior 10 mg flavoured tablets for dogs
- Onsior 20 mg flavoured tablets for dogs
- Onsior 40 mg flavoured tablets for dogs
- Onsior 6 mg flavoured tablets for cats
- Onsior 20 mg/ml solution for injection
Estado regulador
POM-V classification
POM-V classification
Sin datos reguladores para: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
Almacenamiento y estabilidad
Store canine flavored tablets at 25°C (77°F) or less. Store feline flavored tablets at no more than 30°C (86°F). The injection should be stored in the refrigerator (2°-8°C) in its original outer carton.
Información para el cliente
Onsior® (Robenacoxib) es un medicamento utilizado para aliviar el dolor y la inflamación en su mascota. Para asegurar que funcione de manera segura y efectiva, por favor siga estas pautas:
- Para perros: Administre la tableta con el estómago vacío. Adminístrela al menos 30 minutos antes o después de una comida.
- Para gatos: Puede administrar la tableta con o sin una pequeña cantidad de comida. No divida, rompa ni triture las tabletas.
- Manipulación: Lávese las manos después de manipular el medicamento. Las mujeres embarazadas que estén cerca del término del embarazo deben usar guantes al manipular este fármaco.
- Qué observar: Suspenda la administración del medicamento y contacte a su veterinario inmediatamente si su mascota muestra signos de enfermedad, tales como:
- Vómitos o diarrea severos o con sangre
- Pérdida de apetito o letargo extremo (apatía)
- Coloración amarillenta en el blanco de los ojos o en las encías (ictericia)
- Colapso o debilidad
- Nunca administre a su mascota otros medicamentos para el dolor (como aspirina, ibuprofeno u otros AINE veterinarios) o esteroides mientras esté tomando este fármaco sin consultar a su veterinario.
La referencia de medicamentos de VetSheet está destinada a profesionales veterinarios autorizados como ayuda para la toma de decisiones clínicas, no como sustituto del criterio profesional ni del prospecto actual del fabricante.